Scholar Rock Holding Corp

SRRK

Healthcare|Biotechnology|USA

$56.75

-1.26 (-2.17%)

Tangible Book

$2.32

Earnings Power

$2.96

Upcoming Data Readouts (3)

Nov 2026

Est. completion

P3Spinal Muscular Atrophy

Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

Dec 2026

Est. completion

P1Healthy

A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults

Nov 2028

Est. completion

P2Spinal Muscular Atrophy

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026

Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).